In his debut blog, Nick Meader tackles a huge umbrella review of youth mental health interventions, which presents the efficacy and acceptability of 72 different approaches to help children and young people.
[read the full story...]
Raphael Rifkin-Zybutz and Sameer Jauhar summarise the recently published ANTLER trial, which explores whether antidepressant maintenance can reduce the risk of relapse in depression.
[read the full story...]
Susannah Murphy summarises a new Cochrane review and network meta-analysis, which provides the best evidence to date about new generation antidepressants for depression in children and adolescents.
[read the full story...]
Catherine Harmer summarises a recent network meta-analysis relating to her own Wellcome Trust funded research into antidepressants for young people with anxiety or depression.
[read the full story...]
Andrew Shepherd considers the implications of a recent network meta-analysis of the efficacy and tolerability of antidepressants for children and adolescents with depression.
[read the full story...]
Samei Huda discusses the findings of a recent review into suicidality and aggression during antidepressant treatment. The systematic review and meta-analyses were based on clinical study reports and included some important adverse effects of antidepressants in children and young people.
[read the full story...]
In addition to its impact on quality of life, panic disorder can have a number of costly consequences such as lost productivity – particularly if also associated with agoraphobia. Cost-effectiveness is therefore an important consideration in choosing the optimal treatment for panic disorder, which might improve value via the cost side of the equation. A recent [read the full story…]
Depression is common in primary care and associated with a substantial personal, social and societal burden. There is considerable ongoing controversy regarding whether antidepressant pharmacotherapy works and, in particular, for whom. One widely-prescribed antidepressant is fluoxetine (Prozac), an antidepressant of the selective serotonin reuptake inhibitors (SSRI) class. Although a number of more recent antidepressants are [read the full story…]
